PeptidesRx Review: It Names Its Pharmacy, Then Says That Pharmacy Cannot Make This

"An FDA-registered 503B pharmacy"

Set against that, here is the sentence that appears, with only the product name swapped, on twenty-six pages:

Safety is our first priority. Every prescription is reviewed by a U.S.-licensed clinician, filled with USP-grade [product] at an FDA-registered 503B pharmacy, and third-party tested for potency and sterility before it ships.

Section 503B is a real designation and, unusually in this category, it is the right one to want: an outsourcing facility registers with FDA, is subject to FDA inspection and to current good manufacturing practice, and can make sterile products in batches. It is also a register you can read. 503A and 503B are not two words for the same thing, and the difference is exactly what a claim like this is trading on.

FDA publishes the list of registered outsourcing facilities. ¹ On 9 August 2026 it was searched for "Jungle", "F&F" and "Fairfield". None of the three returns anything. The Ohio entries on that list are STAQ Pharma of Ohio in Columbus, Wedgewood Connect Ohio in Albany, and RC Outsourcing in Lowellville — three different companies, in three different cities, from the one PeptidesRx names.

So one of two things is true, and the site does not say which. Either the sterile injectables are filled by some other facility that PeptidesRx never names — in which case the disclosure that made this company look better than its competitors does not cover the products it sells — or the 503B sentence on twenty-six pages describes a status the named pharmacy does not hold.

That is the whole review, and everything below is a variation on it.

The wrong drug, in the sentence about the drug

If the 503B claim were the only defect it might be a wording problem. It is not, and what surrounds it is worse than a wording problem, because it is checkable in a browser in about a minute.

Two product pages tell a customer their vial was filled with BPC-157 when the product is a lipotropic injection. The PT-141 page runs its entire "why buy at home" comparison under the heading of a different peptide.

These are not typos in a blog post. They are in the safety paragraph, on the page where the purchase happens, describing what is in the syringe.

"Passed", four times, on everything

Each product page carries a panel headed Quality tested. It has four rows and, on every product, every row reads Passed.

• Customized plan — Passed — "Confirmed every 3–6 months to stay within ± 10 % of the target strength"
• Sterility test — Passed — "Screened for bacteria, fungi, and other contaminants to meet USP 797 standards"
• Endotoxicity test — Passed — "Checked to USP 85 limits to ensure zero harmful bacterial toxins"
• pH test — Passed — "Fine-tuned for a smooth, irritation-free injection"

Read the first row again. Its caption describes a potency test — ±10% of target strength, confirmed every three to six months — and its label says "Customized plan". The label has been overwritten with copy from somewhere else, which tells you how much attention the panel has had.

More to the point: no lot number, no date, no laboratory name and no document appears anywhere near it. Across all 62 pages in the sitemap, the strings "certificate of analysis" and "COA" occur zero times. A permanent "Passed" attached to no lot is a graphic, not a result — and a certificate of analysis is a document, not a posture.

The sentence beside the panel adds one more thing worth noting: medication is "independently verified in FDA- and DEA-registered labs". DEA registration governs controlled substances. Nothing in this catalogue is one.

USP-grade what, exactly?

The word doing the most work in that safety sentence is "USP-grade", and it appears attached to some substances that have no USP monograph to be graded against.

Scattered through the site — in the package copy on /home-new/ and in template strings leaking onto other product pages — the same construction appears for BPC-157, MOTS-C and CJC-1295.

Those three are not obscure. FDA names all three on its published page of bulk drug substances that may present significant safety risks, together with AOD-9604, epitalon, ipamorelin and thymosin beta-4 fragment (TB-500) — and every one of those seven appears in PeptidesRx's advertised monthly packages. ¹⁴ FDA's stated reason for MOTs-C is that the agency "has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration."

A substance FDA has flagged for having no human exposure data does not have a United States Pharmacopeia monograph. "USP-grade" is being used the way "pharmaceutical grade" is used elsewhere in this industry: as a texture rather than a standard.

The monograph question is not decorative, either. Under section 503A a compounder may use a bulk drug substance only if it complies with a USP or NF monograph, or is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. ² For BPC-157, MOTS-C, CJC-1295, epitalon, AOD-9604 and TB-500, none of the three doors is open — which is precisely why they are on the safety-risk page rather than the bulks list.

The packages that cannot be bought

Follow the monthly-plans button and the picture gets stranger.

That button sits in the global popup on every page of the site. It points at `peptidesinc.com/subscription-packages/`. On 9 August 2026 that URL returned HTTP 404.

The only page that does list the packages is `/home-new/`, which is in the published sitemap and therefore indexable. It advertises six monthly plans from $99 to $499, containing AOD-9604, BPC-157 capsules, NAD+, Pinealon, epitalon, GHK-Cu, glutathione, a BPC-157 + TB-500 blend, CJC-1295 + ipamorelin, tirzepatide and tesamorelin.

So the peptides that would make this a peptide company — BPC-157, TB-500, CJC-1295, epitalon, MOTS-C — are advertised on an indexed page, are not purchasable, and are reachable only through a site-wide button that 404s. What can actually be bought is eighteen SKUs of sermorelin, PT-141, NAD+, glutathione, GHK-Cu cream, tretinoin, B12, lipotropics, methylene blue, ondansetron, hormone products, and compounded GLP-1s.

What the evidence says about what can be bought

Take the four peptides on the live shop in turn.

Sermorelin, $176, sold as an injection or oral capsules, for "recovery… metabolism… energy… sleep quality… anti-aging benefits". As of 9 August 2026 a PubMed search for sermorelin restricted to randomised controlled trials returns 19 records, the newest from August 2005. ^{3 4} Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None measures sleep, recovery, metabolism or body composition. And no registered trial has tested an oral sermorelin capsule at all — the secretagogue family rewards reading one molecule and one route at a time.

PT-141, $289, "addressing sexual dysfunction in men and women". This one has real evidence, and it is in one sex. Bremelanotide's two phase 3 trials, NCT02333071 and NCT02338960, randomised 723 and 714 premenopausal women with hypoactive sexual desire disorder. ^{5 6} The approved product built on them is Vyleesi, whose label says in consecutive sentences: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance." ⁷ A registry search restricted to erectile dysfunction as a condition returns zero studies. The women's half of PeptidesRx's claim is well supported; the men's half is not.

NAD+, $189, injection or nasal spray, for energy, focus, DNA repair, detoxification and sleep. Four randomised trials mention injected NAD+ and only one administers it, in ischaemic heart failure. ^{8 9} None of the six benefits on the page has been measured, and no registered trial tests a nasal spray in any indication.

Glutathione, $156, for "liver detox… brighter, clearer-looking skin and improved energy". Seven randomised records match injected glutathione with skin, detoxification, fatigue or energy; the nearest is a four-ingredient injectable cocktail for pigmentation from which nothing about glutathione alone follows. ¹⁰

The compounded semaglutide, at $199, is the one product with a major trial behind the molecule — STEP 1 randomised 1,961 adults and reported −14.9% against −2.4% on placebo. ^{11 12} But the listing also sells "oral drops" and "dissolvable melts", neither of which has a registered trial or published bioavailability, and the compounded preparation is not the trial drug in any presentation. Nothing on the page explains why a copy of a commercially available approved drug is being compounded: an FDA drug-shortage database query on 9 August 2026 returned only "Semaglutide Tablet — To Be Discontinued" entries, with no injection in shortage. ¹³

The disclaimers still belong to a different company

One last pattern, because it explains several of the others.

The /disclaimer page is titled "Disclaimers" and is written, in its entirety, about a single product:

NAD+ is prescribed by licensed medical providers in compliance with applicable laws… NAD+ should be used under the supervision of a licensed provider… We do not sell or ship to states where NAD+ prescribing is prohibited.

The terms of service devote clause 4 to "NAD+ Prescriptions". There are twenty-six products in the catalogue.

And the global footer, on all 62 pages — including sermorelin, PT-141, glutathione and compounded semaglutide — carries the formula Congress wrote for dietary supplements:

These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease.

That sentence belongs on a bottle of magnesium. On a page selling a prescription sterile injectable it replaces the one disclosure a buyer most needs — that the preparation is compounded, is not FDA-approved, and has not been reviewed by FDA for safety, effectiveness or quality.

Why this page carries no link

This site links to providers it reviews, including ones it criticises sharply. It is not doing so here, and the reason is narrow enough to state precisely.

Nothing in this catalogue is research-use-only material, so the rule that would force this automatically does not apply. The judgement is about the one question this whole site exists to ask: who fills the prescription, under which regulatory section, and where are they licensed? PeptidesRx answers that question twice, on its own pages, and the two answers cannot both be true — a named pharmacy that "cannot dispense sterile compounds", and twenty-six pages of sterile injectables filled "at an FDA-registered 503B pharmacy" by a company FDA's register does not list. Two of those pages name a different drug entirely. The button offering monthly plans returns a 404.

None of that is an allegation about the medicine. It is a statement about what can be verified, and right now the answer is: less than the site claims, and less than it claimed three months ago on a domain that is now a placeholder. If the pharmacy statement and the 503B claim are brought into agreement, this decision changes.